Gain Therapeutics GANX 深 沪
已收盘 10-31 16:00:00 美东时间
1.96
+0.200
+11.36%
华盛通- 最 高1.98
- 今 开1.80
- 成交量 113.88万股
- 最 低 1.775
- 昨 收 1.76
- 总市值 7045.93万
- 52周最高 2.81
- 市盈率 静 --
- 换手率 3.17%
- 52周最低 1.41
- 委 比 83.85%
- 总股本 3594.86万
- 历史最高 17.93
- 量 比 2.27
- 振 幅 11.65%
- 历史最低 0.89
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gain Therapeutics to Present at Neuroscience 2025
Gain Therapeutics announced a poster presentation at Neuroscience 2025 showcasing GT-02287, a small molecule allosteric modulator of glucocerebrosidase (GCase), targeting Parkinson's disease (PD) with or without GBA1 mutations. Preclinical data highlights disease-modifying effects, including restored enzymatic function, reduced pathology, and improved motor function in PD models. Phase 1 studies demonstrated favorable safety, tolerability, and ta...
10-30 11:00
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
Gain Therapeutics, Inc. will participate in the 2025 Maxim Growth Summit on October 22-23 at The Hard Rock Hotel NYC. Gene Mack, President and CEO, will join a panel discussion on innovative approaches for neurogenerative diseases in clinical trials. Gain is a clinical-stage biotech company developing next-generation allosteric small molecule therapies for neurodegenerative diseases, rare genetic disorders, and oncology. Its lead candidate, GT-02...
10-16 11:00
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.
10-15 18:04
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Gain Therapeutics will host a virtual KOL event on October 14, 2025, at 4:00 p.m. EST, featuring experts Karl Kieburtz and Kenneth Marek. The event will discuss biomarkers, clinical endpoints, and data from GT-02287, a Phase 1b candidate for Parkinson’s disease. GT-02287 has shown favorable safety and trends of improvement in MDS-UPDRS scores. Preclinical data suggest potential disease-modifying effects. Registration for the event is available on...
10-09 11:00
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
Gain Therapeutics Presents Phase 1b GT-02287 Data At International Congress Of Parkinson's Disease And Movement Disorders, Highlighting Safety, Tolerability, And Exploratory Findings In PD Patients With or Without GBA1 Mutation
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participantsPlasma exposures in patients within projected therapeutic range and comparable to exposures
10-06 20:20
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
<p>Gain Therapeutics reported positive early results from its Phase 1b study of GT-02287 for Parkinson's disease. Participants showed improvement in MDS-UPDRS scores, and the drug was well-tolerated with no serious adverse events. Plasma exposures were within therapeutic ranges. A virtual KOL event on October 14 will discuss the findings. Preclinical data suggest GT-02287 may slow disease progression by restoring GCase enzyme function and reducin...
10-06 12:15
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
Gain Therapeutics' Director of AI, Dr. Rinaldo Montalvão, will present at the WORLD BI DDIP 2025 conference in Barcelona on September 26. His talk, "Transforming Drug Discovery: Generative Models and Electrostatic Complementarity," will focus on AI and automation in drug discovery. Gain Therapeutics specializes in developing next-generation allosteric therapies, with its lead candidate GT-02287 in Phase 1b trials for Parkinson's disease. The comp...
09-23 11:40
